In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality. Only 1 of the first 3 warfarin controlled pivotal nonvitamin k oral anticoagulants trials in af included patients with bioprosthetic valves n80. Methods the biomarker substudy from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation trial included 4850 patients with af randomised to treatment with apixaban or warfarin. A post hoc analysis of the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation aristotle study compared clinical characteristics and outcomes in af patients with a history of cancer taking either apixaban or warfarin. Design post hoc analysis performed in 2015 of results from aristotle apixaban for reduction in stroke and other thromboembolic events in atrial fibrillationa multicentre, double blind, double dummy trial that. Guidelies ade simple af 201 ahaacchrs focused update of the 01 uideline for anagement of patients with atrial fibrillation 6 back to table of contents recommendations for selecting.
The effects of apixaban versus warfarin were consistent in patients with af with and without previous stroke or tia. Effectiveness and safety of apixaban versus warfarin in nonvalvular atrial fibrillation patients in realworld clinical practice a propensitymatched analysis of 76,940 patients. Apixaban, an orally active factor xa inhibitor, has been studied in a phase iii global randomized clinical trial apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation aristotle versus doseadjusted warfarin in patients with nonvalvular atrial fibrillation nvaf. Effectiveness and safety of apixaban versus warfarin in non. Owing to the higher risk of these outcomes in patients with previous stroke or tia, the absolute benefits of apixaban might be greater in this population. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factorbased approach.
Effectiveness and safety of apixaban compared with. Comparison of readmissions among hospitalized nonvalvular atrial fibrillation patients treated with oral anticoagulants in the united states. Although major bleeding was less common with apixaban, at a dose of 5 mg twice daily, than with warfarin in patients with atrial fibrillation, the use of the same dose of apixaban, as compared. Apixaban vs warfarin in patients with atrial fibrillation 1 apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation bottom line in atrial fibrillation af patients with an risk of stroke mean chads2 score 2. This was predominantly attributed to the higher drug price of apixaban, in contrast to lower costs. Apixaban is a novel oral factor xa inhibitor with rapid.
These data were presented as an oral abstract april 3, 2016 at. The efficacy clinical event rates per 100 patientyears and safety data were. If a patient is on dialysis and is above the age of 80 or weighs under 60 kg then the dose is reduced to 2. Safety and effectiveness of reduceddose apixaban in. Nonvitamin k oral anticoagulants noacs are effective alternatives to warfarin due to their proven efficacy in reducing stroke and thromboembolic events and safer profile.
It is the most common arrhythmia and a major source of morbidity and. Randomized evaluation of decision support interventions. Apixaban, sold under the brand name eliquis among others, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation. Stroke prevention in atrial fibrillation thrombosis canada. Costeffectiveness of apixaban versus warfarin in chinese. In the large aristotele study apixaban was superior to warfarin, it reduced the primary endpoint of stroke and systemic embolism caused less bleeding and reduced allcause mortality. Professor paulus kirchhof, international chief investigator of the trial, said. Apixaban in atrial fibrillation registry full text view.
Apixaban was shown to be safer than warfarin, with superior reduction in the risk of stroke, systemic embolism, mortality, and major bleeding irrespective of kidney function. Although trials have individually compared apixaban and rivaroxaban with warfarin in patients with atrial fibrillation. Ahaasa scientific statement oral antithrombotic agents. Comparison of the safety and effectiveness of apixaban. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in frail patients with nonvalvular atrial fibrillation. Patients with atrial fibrillation af and a calculated cha 2 ds 2vasc score. The superiority on efficacy and safety outcomes of apixaban compared with warfarin persists across weight groups, with even greater reductions in major bleeding in patients with atrial fibrillation.
Objectives compare the effect of apixaban and warfarin on coagulation and primary haemostasis biomarkers in atrial fibrillation af. The optimal anticoagulation strategy for patients with atrial fibrillation af and bioprosthetic valve bpv replacement or native valve repair remains uncertain. The cost of treating one patient with apixaban was usd 1,228 more than warfarin table 2. Aspirin plus traditional chinese medicine for stroke prevention in patients with atrial fibrillation to compare efficacy and safety of aspirin plus. Atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin. Backgroundvitamin k antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Warfarin use for stroke prevention in atrial fibrillation af patients with chronic kidney disease is debated. It occurred in 22 patients randomised to apixaban and 23 randomised to vka. Comparison of dabigatran, rivaroxaban, and apixaban for. Costeffectiveness analysis of apixaban against warfarin for. Jun 15, 2016 objective to determine whether the treatment effect of apixaban versus warfarin differs with increasing numbers of concomitant drugs used by patients with atrial fibrillation. Efficacy and safety of nonvitamin k anticoagulants for. The patient decision aid pda is an interactive website designed for use by a participant without the need of their clinician present.
Background patients with liver disease have increased risk of thrombosis and bleeding but are typically excluded from trials of direct oral anticoagulant agents. Efficacy and safety of apixaban versus warfarin in. Critique of apixaban versus warfarin in patients with. Thus, the objective of this study was to evaluate the safety and effectiveness of apixaban versus warfarin in patients. Apixaban is a novel oral direct factor xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin. Four new oral anticoagulants compare favourably with warfarin for stroke prevention in patients with atrial fibrillation. Patients with af and previous stroke or transient ischaemic attack tia have a high risk of stroke. Apixaban is a safe alternative to warfarin during catheter. Costeffectiveness analysis of apixaban versus edoxaban in. Objective to determine whether the treatment effect of apixaban versus warfarin differs with increasing numbers of concomitant drugs used by patients with atrial fibrillation. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation.
Apixaban is a novel oral direct factor xa inhibitor that has been shown to reduce the risk of stroke in a similar. The results show that apixaban is a safe alternative to warfarin during catheter ablation of atrial fibrillation in patients at risk of stroke. Direct comparison of dabigatran, rivaroxaban, and apixaban. Edoxaban for the prevention of thromboembolism in patients. Renal hemodialysis patients allocated apixaban versus. Nationwide retrospective cohort study based on swedish quality registries. Jun 15, 2016 a smaller reduction in major bleeding was seen with apixaban versus warfarin with increasing numbers of concomitant drugs p interaction 0. Most patients took doacs for atrial fibrillation, and few took doacs for venous thromboembolism. The 2011 apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation aristotle trial randomized 18,201 patients with nonvalvular af and. Efficacy and safety of apixaban compared with warfarin.
Apixaban in patients with atrial fibrillation nejm. Nonmajor bleeding with apixaban versus warfarin in patients. We evaluated the safety and efficacy of apixaban vs warfarin in patients with af and a history of bpv replacement or native valve repair. Critique of apixaban versus warfarin in patients with atrial. Objective to determine whether the treatment effect of apixaban versus warfarin differs with increasing numbers of concomitant drugs used by patients with atrial fibrillation design post hoc analysis performed in 2015 of results from aristotle apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation a multicentre, double blind, double dummy trial that. Apixaban is a novel oral direct factor xa inhibitor that. The new england journal of medicine downloaded from on august 28, 2011. Effectiveness and safety of apixaban versus rivaroxaban. Apixaban 5mg po bid was superior to warfarin for v stroke or systemic embolism. The apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation aristotle trial compared apixaban a novel oral direct factor xa inhibitor with warfarin for the prevention of stroke or systemic embolism in patients with af and at least one additional risk factor for stroke. Warfarin has several limitations, including drug and food interactions, a narrow therapeutic range, need for anticoagulation monitoring, and bleeding. In a post hoc analysis of aristotle apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation.
Apixaban vs warfarin in patients with atrial fibrillation 1 apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation. Subsequently apixaban has been approved by the european health authorities for the use in patients with atrial fibrillation. We customized a markov model with ten health states to estimate the lifetime economic and clinical outcomes in 6week cycles. Costutility analysis of apixaban versus warfarin in atrial.
Patients with interacting potentiating drugs for warfarin or apixaban had similar outcomes and consistent treatment effects of apixaban versus warfarin. To compare the safety and effectiveness of apixaban versus rivaroxaban for patients with nonvalvular atrial fibrillation. In the aristotle trial, the rate of stroke or systemic embolism was reduced by apixaban compared with warfarin in patients with atrial fibrillation af. Mdfrom the department of neurology, triemli hospital, zurich, and university of bern, bern, switzerland. Atrial fibrillation is a common arrhythmia that increases the risk of stroke. Nonmajor bleeding with apixaban versus warfarin in patients with atrial. Objectives this study evaluated the pharmacokinetics pk, pharmacodynamics pd, clinical efficacy and safety of edoxaban versus warfarin in patients with atrial fibrillation af and history of liver disease.
Objectives this study evaluated the pharmacokinetics pk, pharmacodynamics pd, clinical efficacy and safety of edoxaban versus warfarin in patients with atrial fibrillation. Warfarin is very effective at preventing stroke in patients with atrial fibrillation. Cancer is an important condition associated with development of af 2,3. It provides information about the atrial fibrillation diagnosis. Design post hoc analysis performed in 2015 of results from aristotle apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation. Aristotle was a randomized, double blind, doubledummy trial that compared apixaban 5 mg twice daily with warfarin to a target international normalized ratio of 23 in 18 201 patients with af. Apixaban versus warfarin in patients with atrial fibrillation. Apixaban and rivaroxaban are newer blood thinners that are being recommended over warfarin because of their improved safety.
Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. Effect of apixaban compared with warfarin on coagulation. Renal hemodialysis patients allocated apixaban versus warfarin in atrial fibrillation renalaf november 16, 2019. We performed a network metaanalysis nma comparing the efficacy stroke or systemic embolism and safety major bleeding among different nonvitamin k antagonist oral anticoagulants noacs in patients with atrial fibrillation. Although trials have individually compared apixaban and rivaroxaban with warfarin in patients with atrial fibrillation, few studies have compared the 2 treatments with each other. Apixaban and rivaroxaban are the most commonly prescribed direct oral anticoagulants for adults with atrial fibrillation, but headtohead data comparing their safety and effectiveness are lacking. Anticoagulation in atrial fibrillation patients intechopen. The selection of an antithrombotic agent should be individualized on the basis of risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics including time in inr therapeutic range if the patient has been on warfarin.
Apr 07, 2020 apixaban and rivaroxaban are newer blood thinners that are being recommended over warfarin because of their improved safety. Novel oral anticoagulant versus warfarin in cancer patients. Apixaban is a novel oral direct factor xa inhibitor that has been. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack. Pdf effectiveness and safety of apixaban, dabigatran. We aimed to assess the relative benefit of new oral anticoagulants in key subgroups, and the effects on important secondary outcomes. Comparison of readmissions among hospitalized nonvalvular.
The groups did not statistically differ in patients backgrounds or procedural parameters. Pdf apixaban versus warfarin in patients with atrial. Objective we describe the incidence, location and management of nonmajor bleeding, and assess the association between nonmajor bleeding and clinical outcomes in patients with atrial fibrillation af receiving anticoagulation therapy enrolled in apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation aristotle. Polypharmacy and effects of apixaban versus warfarin in. Apixaban compared with warfarin in patients with atrial. Vitamin k antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. This retrospective study used four large us claims databases.
1019 948 525 574 536 395 1478 271 707 1127 273 359 1424 1303 1241 1496 1371 1354 455 1309 306 990 740 922 1449 696 1339 286 973 640 1288 392 735 807 385 1206 541 1349 1395 1345 275